Non-surgical treatment of adenoidal hypertrophy: The role of treating IgE-mediated inflammation

Pediatric Allergy and Immunology

Volumn 21, Issue 8, 2010, Pages 1095-1106

  Scadding, Glenis ^a  

^a ROYAL NATIONAL THROAT NOSE AND EAR HOSPITAL   (United Kingdom)

Author keywords

Adenoidal hypertrophy; Allergic rhinitis; IgE mediated inflammation; Intranasal corticosteroids

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; BECLOMETASONE DIPROPIONATE; CLAVULANATE POTASSIUM; FLUTICASONE PROPIONATE; IMMUNOGLOBULIN E; MOMETASONE FUROATE; MONTELUKAST; PREDNISOLONE;

ADENOID HYPERTROPHY; ADENOIDECTOMY; ADENOTONSILLECTOMY; ALLERGIC RHINITIS; ALLERGY; ASTHMA; EPISTAXIS; HUMAN; HYPERTROPHY; NOSE IRRITATION; PRIORITY JOURNAL; REVIEW; SLEEP APNEA SYNDROME; THROAT IRRITATION; TREATMENT DURATION;

ADENOIDECTOMY; ADENOIDS; ADOLESCENT; ADRENAL CORTEX HORMONES; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERSENSITIVITY, IMMEDIATE; HYPERTROPHY; INFLAMMATION; RISK;

EID: 78449258673     PISSN: 09056157     EISSN: 13993038     Source Type: Journal    
DOI: 10.1111/j.1399-3038.2010.01012.x     Document Type: Review

References (111)

1. Hellings PW, Fokkens WJ. Allergic rhinitis and its impact on otorhinolaryngology. Allergy 2006: 61: 656-64.
2. Haapaniemi JJ. Adenoids in school-aged children. J Laryngol Otol 1995: 109: 196-2.
3. Kemaloglu YK, Goksu N, Inal E, Akyildiz N. Radiographic evaluation of children with nasopharyngeal obstruction due to the adenoid. Ann Otol Rhinol Laryngol 1999: 108: 67-72.
4. Berlucchi M, Salsi D, Valetti L, Parrinello G, Nicolai P. The role of mometasone furoate aqueous nasal spray in the treatment of adenoidal hypertrophy in the pediatric age group: preliminary results of a prospective, randomized study. Pediatrics 2007: 119: e1392-7.
5. Kveton JF, Pillsbury HC III, Sasaki CT. Nasal obstruction: adenoiditis vs adenoid hypertrophy. Arch Otolaryngol 1982: 108: 315-8.
6. Kurnatowski P, Putyński L, Lapienis M, Kowalska B. Neurocognitive abilities in children with adenotonsillar hypertrophy. Int J Pediatr Otorhinolaryngol 2006: 70: 419-24.
7. Suratt PM, Barth JT, Diamond R, et al. Reduced time in bed and obstructive sleep-disordered breathing in children are associated with cognitive impairment. Pediatrics 2007: 119: 320-9.
8. Bass JL, Corwin M, Gozal D, et al. The effect of chronic or intermittent hypoxia on cognition in childhood: a review of the evidence. Pediatrics 2004: 114: 805-16.
9. Beebe DW, Wells CT, Jeffries J, Chini B, Kalra M, Amin R. Neuropsychological effects of pediatric obstructive sleep apnea. J Int Neuropsychol Soc 2004: 10: 962-75.
10. Kennedy JD, Blunden S, Hirte C, et al. Reduced neurocognition in children who snore. Pediatr Pulmonol 2004: 37: 330-7.
11. Görür K, Döven O, ÜNal M, Akkuş N, ÖZcan C. Preoperative and postoperative cardiac and clinical findings of patients with adenotonsillar hypertrophy. Int J Pediatr Otorhinolaryngol 2001: 59: 41-6.
12. Tal A, Leiberman A, Margulis G, Sofer S. Ventricular dysfunction in children with obstructive sleep apnea: radionuclide assessment. Pediatr Pulmonol 1988: 4: 139-43.
13. Sofer S, Weinhouse E, Tal A, et al. Cor pulmonale due to adenoidal or tonsillar hypertrophy or both in children: noninvasive diagnosis and follow-up. Chest 1988: 93: 119-22.
14. Amin RS, Kimball TR, Bean JA, et al. Left ventricular hypertrophy and abnormal ventricular geometry in children and adolescents with obstructive sleep apnea. Am J Respir Crit Care Med 2002: 165: 1395-9.
15. Marcus CL, Greene MG, Carroll JL. Blood pressure in children with obstructive sleep apnea. Am J Respir Crit Care Med 1998: 157(4 Pt 1): 1098-103.
16. Huang S-W, Giannoni C. The risk of adenoid hypertrophy in children with allergic rhinitis. Ann Allergy Asthma Immunol 2001: 87: 350-5.
17. Grimmer JF, Poe DS. Update on eustachian tube dysfunction and the patulous eustachian tube. Curr Opin Otolaryngol Head Neck Surg 2005: 13: 277-82.
18. Egeli E, Oghan F, Ozturk O, Harputuoglu U, Yazici B. Measuring the correlation between adenoidal-nasopharyngeal ratio (AN ratio) and tympanogram in children. Int J Pediatr Otarhinolaryngol 2005: 69: 229-33.
19. Al-Mazrou KA, Al-Khattaf AS. Adherent biofilms in adenotonsillar diseases in children. Arch Otolaryngol Head Neck Surg 2008: 134: 20-3.
20. Galli J, Calo L, Ardito F, et al. Biofilm formation by Haemophilus influenzae isolated from adeno-tonsil tissue samples, and its role in recurrent adenotonsillitis. Acta Otorhinolaryngolotica Italica 2007: 27: 134-8.
21. Macassey E, Dawes P. Biofilms and their role in otorhinolaryngological disease. J Laryngol Otol 2008: 122: 1273-8.
22. Modrzyński M, Mierzwinski J, Zawisza E, Piziewicz A. Acoustic rhinometry in the assessment of adenoid hypertrophy in allergic children. Med Sci Monit 2004: 10: CR341-8.
23. Georgalas C, Thomas K, Owens C, Abramovich S, Lack G. Medical treatment for rhinosinusitis associated with adenoidal hypertrophy in children: an evaluation of clinical response and changes on magnetic resonance imaging. Ann Otol Rhinol Laryngol 2005: 114: 638-44.
24. Modrzynski M, Zawisza E. An analysis of the incidence of adenoid hypertrophy in allergic children. Int J Pediatr Otorhinolaryngol 2007: 71: 713-9.
25. Ganzer U, Bachert C. Localization of IgE synthesis in immediate-type allergy of the upper respiratory tract. ORL J Otorhinolaryngol Relat Spec 1988: 50: 257-64.
26. Papatziamos G, Van Der Ploeg I, Hemlin C, Patwardhan A, Scheynius A. Increased occurrence of IgE+ and FcεRI+ cells in adenoids from atopic children. Allergy 1999: 54: 916-25.
27. Fokkens WJ, Vinke JG, De Jong SS, Bogaert DP, Kleinjan A, Eichhorn E. Differences in cellular infiltrates in the adenoid of allergic children compared with age- and gender-matched controls. Clin Exp Allergy 1998: 28: 187-95.
28. Nguyen LH, Manoukian JJ, Sobol SE, et al. Similar allergic inflammation in the middle ear and the upper airway: evidence linking otitis media with effusion to the united airways concept. J Allergy Clin Immunol 2004: 114: 1110-5.
29. Fokkens WJ, Bruijnzeel-Koomen CA, Vroom TM, et al. The Langerhans cell: an underestimated cell in atopic disease. Clin Exp Allergy 1990: 20: 627-38.
30. Gates GA, Muntz HR, Gaylis B. Adenoidectomy and otitis media. Ann Otol Rhinol Laryngol 1992: 101: 24-32.
31. Brodsky L. Modern assessment of tonsils and adenoids. Pediatr Clin North Am 1989: 36: 1551-69.
32. Maw AR, Parker A. Surgery of the tonsils and adenoids in relation to secretory otitis media in children. Acta Otolaryngol Suppl 1988: 454: 202-7.
33. American Academy of Pediatrics. Clinical practice guideline: diagnosis and management of childhood obstructive sleep apnea syndrome. Pediatrics 2002: 109: 704-12.
34. Lipton AJ, Gozal D. Treatment of obstructive sleep apnea in children: do we really know how? Sleep Med Rev 2003: 7: 61-80.
35. Shintani T, Asakura K, Kataura A. The effect of adenotonsillectomy in children with OSA. Int J Pediatr Otorhinolaryngol 1998: 44: 51-8.
36. Suen JS, Arnold JE, Brooks LJ. Adenotonsillectomy for treatment of obstructive sleep apnea in children. Arch Otolaryngol Head Neck Surg 1995: 121: 525-30.
37. Nieminen P, Tolonen U, Löppönen H. Snoring and obstructive sleep apnea in children: a 6-month follow-up study. Arch Otolaryngol Head Neck Surg 2000: 126: 481-6.
38. Wiet GJ, Bower C, Seibert R, Griebel M. Surgical correction of obstructive sleep apnea in the complicated pediatric patient documented by polysomnography. Int J Pediatr Otorhinolaryngol 1997: 41: 133-43.
39. ÅGren K, Nordlander B, Linder-Aronsson S, Zettergren-Wijk L, Svanborg E. Children with nocturnal upper airway obstruction: postoperative orthodontic and respiratory improvement. Acta Otolaryngol 1998: 118: 581-7.
40. Stradling JR, Thomas G, Warley ARH, Williams P, Freeland A. Effect of adenotonsillectomy on nocturnal hypoxaemia, sleep disturbance, and symptoms in snoring children. Lancet 1990: 335: 249-53.
41. Kudoh F, Sanai A. Effect of tonsillectomy and adenoidectomy on obese children with sleep-associated breathing disorders. Acta Otolaryngol Suppl 1996: 523: 216-8.
42. Nishimura T, Morishima N, Hasegawa S, Shibata N, Iwanaga K, Yagisawa M. Effect of surgery on obstructive sleep apnea. Acta Otolaryngol Suppl 1996: 523: 231-3.
43. Joshua B, Bahar G, Sulkes J, Shpitzer T, Raveh E. Adenoidectomy: long-term follow-up. Otolaryngol Head Neck Surg 2006: 135: 576-80.
44. Buchinsky FJ, Lowry MA, Isaacson G. Do adenoids regrow after excision? Otolaryngol Head Neck Surg 2000: 123: 576-81.
45. Lesinskas E, Drigotas M. The incidence of adenoidal regrowth after adenoidectomy and its effect on persistent nasal symptoms. Eur Arch Otorhinolaryngol 2009: 266: 469-73.
46. Richter GT, Bower CM. Cervical complications following routine tonsillectomy and adenoidectomy. Curr Opin Otolaryngol Head Neck Surg 2006: 14: 375-80.
47. Windfuhr JP, Chen YS, Remmert S. Hemorrhage following tonsillectomy and adenoidectomy in 15, 218 patients. Otolaryngol Head Neck Surg 2005: 132: 281-6.
48. Vera-Llonch M, Hagiwara M, Oster G. Clinical and economic consequences of bleeding following major orthopedic surgery. Thromb Res 2006: 117: 569-77.
49. Steiner ME, Despotis GJ. Transfusion algorithms and how they apply to blood conservation: the high-risk cardiac surgical patient. Hematol Oncol Clin North Am 2007: 21: 177-84.
50. Hopkins C, Browne J, Slack R, Brown P. Variation in day-case nasal surgery - why cannot we improve our day-case rates? Clin Otolaryngol 2007: 31: 12-8.
51. Van Den Akker EH, Sanders EA, Van Staaij BK, et al. Long-term effects of pediatric adenotonsillectomy on serum immunoglobulin levels: results of a randomized controlled trial. Ann Allergy Asthma Immunol 2006: 97: 251-6.
52. Friday GA Jr, Paradise JL, Rabin BS, Colborn DK, Taylor FH. Serum immunoglobulin changes in relation to tonsil and adenoid surgery. Ann Allergy 1992: 69: 225-30.
53. Demain JG, Goetz DW. Pediatric adenoidal hypertrophy and nasal airway obstruction: reduction with aqueous nasal beclomethasone. Pediatrics 1995: 95: 355-64.
54. Brouillette RT, Manoukian JJ, Ducharme FM, et al. Efficacy of fluticasone nasal spray for pediatric obstructive sleep apnea. J Pediatr 2001: 138: 838-44.
55. Criscuoli G, D'Amora S, Ripa G, et al. Frequency of surgery among children who have adenotonsillar hypertrophy and improve after treatment with nasal beclomethasone. Pediatrics 2003: 111: e236-8.
56. Cengel S, Akyol MU. The role of topical nasal steroids in the treatment of children with otitis media with effusion and/or adenoid hypertrophy. Int J Pediatr Otorhinolaryngol 2006: 70: 639-45.
57. Papatziamos G, Van Hage-Hamsten M, Lundahl J, Hemlin C. IgE-positive plasma cells are present in adenoids of atopic children. Acta Otolaryngol 2006: 126: 180-5.
58. Goldbart AD, Goldman JL, Veling MC, Gozal D. Leukotriene modifier therapy for mild sleep-disordered breathing in children. Am J Respir Crit Care Med 2005: 172: 364-70.
59. Goldbart AD, Godman GL, Li RC, Brittian KR, Tauman R, Gozal D. Differential expression of cysteinyl leukotriene receptors 1 and 2 in tonsils of children with obstructive sleep apnea and recurrent infection. Chest 2004: 126: 13-8.
60. Kondo N, Katsunuma T, Odajima Y, Morikawa A. A randomized open-label comparative study of montelukast versus theophylline added to inhaled corticosteroid in asthmatic children. Allergol Int 2006: 55: 287-93.
61. Ostrom NK, Decotis BA, Lincourt WR, et al. Comparative efficacy and safety of low-dose fluticasone propionate and montelukast in children with persistent asthma. J Pediatr 2005: 147: 213-20.
62. Karaman O, Sünneli L, Uzuner N, et al. Evaluation of montelukast in 8 to 14 year old children with mild persistent asthma and compared with inhaled corticosteroids. Allergol Immunopathol (Madr) 2004: 32: 21-7.
63. Knorr B, Granchi LM, Bisgaard H, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 2001: 108: e48.
64. Storms W, Michele TM, Knorr B, et al. Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients aged > or = 6 years. Clin Exp Allergy 2001: 31: 77-87.
65. Maspero JF, Duenas-Meza E, Volovitz B, et al. Oral montelukast versus inhaled beclomethasone in 6- to 11-year-old children with asthma: results of an open-label extension study evaluating long-term safety, satisfaction, and adherence with therapy. Curr Med Res Opin 2001: 17: 96-104.
66. Van Adelsberg J, Moy J, Wei LX, Tozzi CA, Knorr B, Reiss TF. Safety, tolerability, and exploratory efficacy of montelukast in 6- to 24-month-old patients with asthma. Curr Med Res Opin 2005: 21: 971-9.
67. Szefler SJ, Baker JW, Uryniak T, Goldman M, Silkoff PE. Comparative study of budesonide inhalation suspension and montelukast in young children with mild persistent asthma. J Allergy Clin Immunol 2007: 120: 1043-50.
68. 2LEN, and AllerGen). Allergy 2008: 63 (Suppl. 86): 8-160.
69. Van Cauwenberge P, Bachert C, Passalacqua G, et al. Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy 2000: 55: 116-34.
70. Rak S, Jacobson MR, Sudderick RM, et al. Influence of prolonged treatment with topical corticosteroid (fluticasone propionate) on early and late phase nasal responses and cellular infiltration in the nasal mucosa after allergen challenge. Clin Exp Allergy 1994: 24: 930-9.
71. Goldbart AD, Veling MC, Goldman JL, Li RC, Brittian KR, Gozal D. Glucocorticoid receptor subunit expression in adenotonsillar tissue of children with obstructive sleep apnea. Pediatr Res 2005: 57: 232-6.
72. Hamilos DL, Leung DY, Muro S, et al. GRβ expression in nasal polyp inflammatory cells and its relationship to the anti-inflammatory effects of intranasal fluticasone. J Allergy Clin Immunol 2001: 108: 59-68.
73. Modrzyński M, Zawisza E, Mazurek H. The influence of medical treatment of the perennial allergic rhinitis on the adenoid size in children. Otolaryngol Pol 2006: 60: 543-50.
74. McNicholas WT, Tarlo S, Cole P, et al. Obstructive apneas during sleep in patients with seasonal allergic rhinitis. Am Rev Respir Dis 1982: 126: 625-8.
75. Lavie P, Gertner R, Zomer J, Podoshin L. Breathing disorders in sleep associated with "microarousals" in patients with allergic rhinitis. Acta Otolaryngol 1981: 92: 529-33.
76. Craig TJ, Teets S, Lehman EB, Chinchilli VM, Zwillich C. Nasal congestion secondary to allergic rhinitis as a cause of sleep disturbance and daytime fatigue and the response to topical nasal corticosteroids. J Allergy Clin Immunol 1998: 101: 633-7.
77. Hughes K, Glass C, Ripchinski M, et al. Efficacy of the topical nasal steroid budesonide on improving sleep and daytime somnolence in patients with perennial allergic rhinitis. Allergy 2003: 58: 380-5.
78. Craig TJ, Hanks CD, Fisher LH. How do topical nasal corticosteroids improve sleep and daytime somnolence in allergic rhinitis? J Allergy Clin Immunol 2005: 116: 1264-6.
79. Craig TJ, Mende C, Hughes K, Kakumanu S, Lehman EB, Chinchilli V. The effect of topical nasal fluticasone on objective sleep testing and the symptoms of rhinitis, sleep, and daytime somnolence in perennial allergic rhinitis. Allergy Asthma Proc 2003: 24: 53-8.
80. Ratner PH, Howland WC III, Arastu R, et al. Fluticasone propionate aqueous nasal spray provided significantly greater improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared with montelukast. Ann Allergy Asthma Immunol 2003: 90: 536-42.
81. Kiely JL, Nolan P, McNicholas WT. Intranasal corticosteroid therapy for obstructive sleep apnoea in patients with co-existing rhinitis. Thorax 2004: 59: 50-5.
82. Gurevich F, Glass C, Davies M, et al. The effect of intranasal steroid budesonide on the congestion-related sleep disturbance and daytime somnolence in patients with perennial allergic rhinitis. Allergy Asthma Proc 2005: 26: 268-74.
83. Berlucchi M, Valetti L, Parrinello G, Nicolai P. Long-term follow-up of children undergoing topical intranasal steroid therapy for adenoidal hypertrophy. Int J Pediatr Otorhinolaryngol 2008: 72: 1171-5.
84. Ciprandi G, Varricchio A, Capasso M, et al. Intranasal flunisolide treatment in children with adenoidal hypertrophy. Int J Immunopathol Pharmacol 2007: 20: 833-6.
85. Varricchio A, Tortoriello G, Capasso M, et al. Prevention of surgery in children with adenoidal hypertrophy treated with intranasal flunisolide: a 12-month follow-up. J Biol Regul Homeost Agents 2009: 23: 95-101.
86. Nsouli T. Mometasone furoate reduces severity of adenoidal hypertrophy. Otolaryngol Head Neck Surg 2008: 139 (Suppl. 1): 112-3.Abstract S102.
87. Zhang L, Mendoza-Sassi RA, César JA, Chadha NK. Intranasal corticosteroids for nasal airway obstruction in children with moderate to severe adenoidal hypertrophy. Cochrane Database Syst Rev 2008: 16: CD006286.
88. Zitt M, Kosoglou T, Hubbell J. Mometasone furoate nasal spray: a review of safety and systemic effects. Drug Saf 2007: 30: 317-26.
89. Stanbury RM, Graham EM. Systemic corticosteroid therapy-side effects and their management. Br J Ophthalmol 1998: 82: 704-8.
90. Allen DB. Systemic effects of intranasal steroids: an endocrinologist's perspective. J Allergy Clin Immunol 2000: 106: S179-90.
91. Richards DH, Daley-Yates PT. Choice of inhaled and intranasal steroids when used in combination for asthma and rhinitis in children. Allergy 2000: 55 (Suppl.): 61. Abstract 185.
92. Lumry WR. A review of the preclinical and clinical data of newer intranasal steroids used in the treatment of allergic rhinitis. J Allergy Clin Immunol 1999: 104 (4 pt 1): S150-8.
93. Daley-Yates PT, McAllister T. Systemic bioavailability of fluticasone propionate administered as nasal drops (FP-Drops) and aqueous nasal spray formulations (FPANS). Allergy 1998: 53: 158. Abstract P412.
94. Allen A, Down G, Newland A, et al. Absolute bioavailability of intranasal fluticasone furoate in healthy subjects. Clin Ther 2007: 29: 1415-20.
95. Daley-Yates PT, Richards DH. Pharmacokinetic (PK) and pharmacodynamic (PD) relationships for intranasal corticosteroids (INSs). J Allergy Clin Immunol 2001: 107: S313. Abstract 1023.
96. Schenkel EJ, Skoner DP, Bronsky EA, et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics 2000: 105: e22.
97. Agertoft L, Pedersen S. Short-term lower leg growth rate in children with rhinitis treated with intranasal mometasone furoate and budesonide. J Allergy Clin Immunol 1999: 104: 948-52.
98. Allen DB, Meltzer EO, Lemanske RF Jr, et al. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. Allergy Asthma Proc 2002: 23: 407-13.
99. Skoner D, Gentile D, Angelini B, Kane R, Birdsall D, Banerji D. The effects of intranasal triamcinolone acetonide and intranasal fluticasone propionate on short-term bone growth and HPA axis in children with allergic rhinitis. Ann Allergy Asthma Immunol 2003: 90: 56-62.
100. Murphy K, Uryniak T, Simpson B, O'Dowd L. Growth velocity in children with perennial allergic rhinitis treated with budesonide aqueous nasal spray. Ann Allergy Asthma Immunol 2006: 96: 723-30.
101. Brannan MD, Herron JM, Affrime MB. Safety and tolerability of once-daily mometasone furoate aqueous nasal spray in children. Clin Ther 1997: 19: 1330-9.
102. Cutler DL, Banfield C, Affrime MB. Safety of mometasone furoate nasal spray in children with allergic rhinitis as young as 2 years of age: a randomized controlled trial. Pediatr Asthma Allergy Immunol 2006: 19: 146-53.
103. Meltzer EO, Berger WE, Berkowitz RB, et al. A dose-ranging study of mometasone furoate aqueous nasal spray in children with seasonal allergic rhinitis. J Allergy Clin Immunol 1999: 104: 107-14.
104. Ober S, Gentile D, Kairis E, Barnoski K, Doyle W, Skoner D. Growth velocity and HPA axis function during 1-year treatment with triamcinolone acetonide aqueous (TAA) nasal spray in children with allergic rhinitis (AR). J Allergy Clin Immunol 2005: 115: S267. Abstract 1064.
105. Galant SP, Melamed IR, Nayak AS, et al. Lack of effect of fluticasone propionate aqueous nasal spray on the hypothalamic-pituitary-adrenal axis in 2- and 3-year-old patients. Pediatrics 2003: 112: 96-100.
106. Grossman J, Banov C, Bronsky EA, et al. Fluticasone propionate aqueous nasal spray is safe and effective for children with seasonal allergic rhinitis. Pediatrics 1993: 92: 594-9.
107. Fluticasone Propionate Collaborative Pediatric Working Group. Treatment of seasonal allergic rhinitis with once-daily intranasal fluticasone propionate therapy in children. J Pediatr 1994: 125: 628-34.
108. Ngamphaiboon J, Thepchatri A, Chatchatee P, Chumdermpadetsuk S. Fluticasone propionate aqueous nasal spray treatment for perennial allergic rhinitis in children. Ann Allergy Asthma Immunol 1997: 78: 479-84.
109. Salib RJ, Howarth PH. Safety and tolerability profiles of intranasal antihistamines and intranasal corticosteroids in the treatment of allergic rhinitis. Drug Saf 2003: 26: 863-93.
110. Barnes PJ, Pedersen S. Efficacy and safety of inhaled corticosteroids in asthma. Am Rev Respir Dis 1993: 148 (4 pt 2): S1-26.
111. Watanabe T, Fujiyoshi T, Tomonaga K, Mogi G. Adenoids and otitis media with effusion in children. Adv Otorhinolaryngol 1992: 47: 290-6.